Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:pyridinemonocarboxylic acid
go back to main search page
Accession:CHEBI:26420 term browser browse the term
Definition:A monocarboxylic acid in which the carboxy group is attached to a pyridine (or substituted pyridine) ring.
Synonyms:related_synonym: pyridinemonocarboxylic acids
 cyclic_relationship: is_conjugate_acid_of CHEBI:38181


show annotations for term's descendants           Sort by:
 
1-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Dek DEK proto-oncogene decreases chemical synthesis ISO DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide CTD PMID:28558019 NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
JBrowse link
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N(1)-methylnicotinamide CTD PMID:20567778 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] CTD PMID:32298659 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA CTD PMID:18385449 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Retn resistin multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] CTD PMID:32298659 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases import ISO SLC22A1 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:43,972,808...44,068,447 JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases import ISO SLC22A2 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
JBrowse link
4-pyridoxic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Col2a1 collagen type II alpha 1 chain multiple interactions EXP [COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pyridoxic Acid CTD PMID:24709313 NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
JBrowse link
6-aminonicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Eif4a1 eukaryotic translation initiation factor 4A1 multiple interactions ISO [6-Aminonicotinamide co-treated with spautin-1] results in increased degradation of EIF4A1 protein CTD PMID:30821613 NCBI chr10:54,384,345...54,389,853
Ensembl chr10:54,384,347...54,389,858
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases expression
ISO IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of FGF2 protein] CTD PMID:12898533 NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO 6-Aminonicotinamide inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein] CTD PMID:25246272 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO 6-Aminonicotinamide inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 protein] CTD PMID:25246272 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
ISO IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of IL1B protein] CTD PMID:12898533 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
ISO 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT1 protein]; 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT2 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of FGF2 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of IL1B protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of NTF3 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TGFB1 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TNF protein]
6-Aminonicotinamide results in increased expression of IL6 protein
CTD PMID:12898533 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Mt1 metallothionein 1 multiple interactions
increases expression
decreases response to substance
ISO 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT1 protein]
6-Aminonicotinamide results in increased expression of MT1 protein
MT1 protein results in decreased susceptibility to 6-Aminonicotinamide
CTD PMID:11835189 PMID:12898533 NCBI chr19:10,826,032...10,827,048 JBrowse link
G Mt2A metallothionein 2A multiple interactions
increases expression
decreases response to substance
ISO 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT2 protein]
6-Aminonicotinamide results in increased expression of MT2 protein
MT2 protein results in decreased susceptibility to 6-Aminonicotinamide
CTD PMID:11835189 PMID:12898533 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
JBrowse link
G Mt3 metallothionein 3 increases expression ISO 6-Aminonicotinamide results in increased expression of MT3 protein CTD PMID:10785446 NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
JBrowse link
G Ntf3 neurotrophin 3 increases expression
multiple interactions
ISO 6-Aminonicotinamide results in increased expression of NTF3 protein
IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of NTF3 protein]
CTD PMID:12898533 NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO 6-Aminonicotinamide inhibits the reaction [arsenic trioxide results in increased cleavage of PARP1 protein] CTD PMID:25246272 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO 6-Aminonicotinamide results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression
ISO IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TGFB1 protein] CTD PMID:12898533 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
ISO 6-Aminonicotinamide results in increased expression of TNF protein
IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TNF protein]
CTD PMID:12898533 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
Ancriviroc term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Ancriviroc inhibits the reaction [CCL3 protein binds to CCR5 protein] CTD PMID:15644495 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccr5 C-C motif chemokine receptor 5 multiple interactions ISO Ancriviroc inhibits the reaction [CCL3 protein binds to CCR5 protein] CTD PMID:15644495 NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases ethylation
affects metabolic processing
ISO CYP2C9 protein results in decreased ethylation of Ancriviroc
CYP2C9 protein affects the metabolism of Ancriviroc
CTD PMID:16012074 NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases ethylation
affects metabolic processing
ISO CYP3A4 protein results in decreased ethylation of Ancriviroc
CYP3A4 protein affects the metabolism of Ancriviroc
CTD PMID:16012074 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
flunixin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgs1 prostaglandin-endoperoxide synthase 1 decreases activity EXP flunixin results in decreased activity of PTGS1 protein CTD PMID:12967936 NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
JBrowse link
imazamox term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO imazamox binds to and results in decreased activity of NR1H4 protein CTD PMID:21251949 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 affects activity ISO imazamox affects the activity of NR1I2 protein CTD PMID:23611293 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
imazapyr term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO imazapyr binds to and results in decreased activity of NR1H4 protein CTD PMID:21251949 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
isoniazide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin increases expression EXP Isoniazid results in increased expression of A2M mRNA CTD PMID:12883083 NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
decreases expression
EXP [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCB11 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA] CTD PMID:25331106 PMID:32673658 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 increases expression EXP Isoniazid results in increased expression of ABCC1 mRNA CTD PMID:11752103 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
decreases expression
EXP [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCC2 mRNA
Isoniazid results in decreased expression of ABCC2 mRNA
CTD PMID:25331106 PMID:32673658 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions
decreases expression
EXP [Lipopolysaccharides co-treated with Isoniazid] results in increased expression of ABCC3 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA] CTD PMID:25331106 PMID:32673658 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression EXP Isoniazid results in decreased expression of ABCC4 mRNA CTD PMID:32673658 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Abcc6 ATP binding cassette subfamily C member 6 decreases expression EXP Isoniazid results in decreased expression of ABCC6 mRNA CTD PMID:16260000 NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
JBrowse link
G Ace2 angiotensin I converting enzyme 2 decreases expression ISO Isoniazid results in decreased expression of ACE2 mRNA CTD PMID:32808185 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Afp alpha-fetoprotein decreases expression ISO Isoniazid results in decreased expression of AFP mRNA CTD PMID:30008028 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Agpat3 1-acylglycerol-3-phosphate O-acyltransferase 3 increases expression
multiple interactions
EXP Isoniazid results in increased expression of AGPAT3 mRNA
[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA]
CTD PMID:28619387 NCBI chr20:10,330,960...10,415,358
Ensembl chr20:10,384,507...10,415,358
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Isoniazid results in increased expression of AKR1B10 mRNA CTD PMID:28444390 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
JBrowse link
G Alas1 5'-aminolevulinate synthase 1 increases expression ISO Isoniazid results in increased expression of ALAS1 protein CTD PMID:27438535 PMID:30517741 NCBI chr 8:106,876,514...106,889,852
Ensembl chr 8:106,876,514...106,889,917
JBrowse link
G Alb albumin affects binding ISO Isoniazid binds to ALB protein CTD PMID:25489718 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Apoa4 apolipoprotein A4 affects response to substance ISO APOA4 affects the susceptibility to Isoniazid CTD PMID:24848797 NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
JBrowse link
G Apoa5 apolipoprotein A5 multiple interactions
decreases expression
EXP [Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]
Isoniazid results in decreased expression of APOA5 mRNA
CTD PMID:28619387 NCBI chr 8:46,561,180...46,563,818
Ensembl chr 8:46,561,229...46,563,816
JBrowse link
G App amyloid beta precursor protein increases expression ISO Isoniazid results in increased expression of APP mRNA CTD PMID:30008028 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Asl argininosuccinate lyase increases activity
multiple interactions
EXP Isoniazid results in increased activity of ASL protein
[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein]
CTD PMID:28619387 NCBI chr12:26,659,664...26,677,136
Ensembl chr12:26,659,565...26,679,662
JBrowse link
G Atp1b1 ATPase Na+/K+ transporting subunit beta 1 increases expression ISO Isoniazid results in increased expression of ATP1B1 mRNA CTD PMID:30008028 NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
JBrowse link
G Atp5f1b ATP synthase F1 subunit beta affects expression ISO Isoniazid affects the expression of ATP5B mRNA CTD PMID:24848797 NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
JBrowse link
G Atp5mc1 ATP synthase membrane subunit c locus 1 affects expression ISO Isoniazid affects the expression of ATP5G1 mRNA CTD PMID:24848797 NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124
JBrowse link
G Atp5mc3 ATP synthase membrane subunit c locus 3 affects expression ISO Isoniazid affects the expression of ATP5G3 mRNA CTD PMID:24848797 NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
JBrowse link
G Atp5pb ATP synthase peripheral stalk-membrane subunit b affects expression ISO Isoniazid affects the expression of ATP5PB mRNA CTD PMID:24848797 NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
JBrowse link
G Atp5pf ATP synthase peripheral stalk subunit F6 affects expression ISO Isoniazid affects the expression of ATP5J mRNA CTD PMID:24848797 NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO
EXP
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
Isoniazid results in increased expression of BAX mRNA
Isoniazid results in increased expression of BAX protein
chrysin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
Quercetin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
CTD PMID:21419764 PMID:31332904 PMID:33121995 PMID:33771660 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbox1 gamma-butyrobetaine hydroxylase 1 increases expression ISO Isoniazid results in increased expression of BBOX1 mRNA CTD PMID:30008028 NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Isoniazid results in decreased expression of BCL2 mRNA
Isoniazid results in decreased expression of BCL2 protein
Quercetin inhibits the reaction [Isoniazid results in decreased expression of BCL2 protein]
CTD PMID:21419764 PMID:31332904 PMID:33771660 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases cleavage
ISO [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
Isoniazid results in increased expression of CASP3 mRNA
Isoniazid results in increased cleavage of CASP3 protein
acadesine promotes the reaction [Isoniazid results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP3 protein]
CTD PMID:21419764 PMID:23764483 PMID:28556920 PMID:31332904 PMID:33771660 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 increases cleavage
multiple interactions
ISO Isoniazid results in increased cleavage of CASP9 protein
Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP9 protein]
CTD PMID:31332904 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Casr calcium-sensing receptor affects expression EXP Isoniazid affects the expression of CASR mRNA CTD PMID:20623750 NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
JBrowse link
G Cat catalase decreases activity
multiple interactions
EXP
ISO
Isoniazid results in decreased activity of CAT protein
chrysin inhibits the reaction [Isoniazid results in decreased activity of CAT protein]
CTD PMID:33121995 PMID:33771660 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 decreases expression EXP Isoniazid results in decreased expression of CCR2 mRNA CTD PMID:20623750 NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha decreases expression ISO Isoniazid results in decreased expression of CEBPA mRNA; Isoniazid results in decreased expression of CEBPA protein CTD PMID:24128855 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta decreases expression ISO Isoniazid results in decreased expression of CEBPB protein CTD PMID:24128855 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta decreases expression ISO Isoniazid results in decreased expression of CEBPD mRNA; Isoniazid results in decreased expression of CEBPD protein CTD PMID:24128855 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
JBrowse link
G Chpt1 choline phosphotransferase 1 affects response to substance ISO CHPT1 affects the susceptibility to Isoniazid CTD PMID:24848797 NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103
JBrowse link
G Cldn2 claudin 2 increases expression ISO Isoniazid results in increased expression of CLDN2 mRNA CTD PMID:30008028 NCBI chr  X:103,459,870...103,473,794
Ensembl chr  X:103,459,780...103,474,838
JBrowse link
G Cox11 cytochrome c oxidase copper chaperone COX11 affects expression ISO Isoniazid affects the expression of COX11 mRNA CTD PMID:24848797 NCBI chr10:75,458,735...75,465,322
Ensembl chr10:75,458,749...75,465,322
JBrowse link
G Cox17 cytochrome c oxidase copper chaperone COX17 affects expression ISO Isoniazid affects the expression of COX17 mRNA CTD PMID:24848797 NCBI chr11:62,400,733...62,406,507 JBrowse link
G Cox5b cytochrome c oxidase subunit 5B affects expression ISO Isoniazid affects the expression of COX5B mRNA CTD PMID:24848797 NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
JBrowse link
G Cox6a1 cytochrome c oxidase subunit 6A1 affects expression ISO Isoniazid affects the expression of COX6A1 mRNA CTD PMID:24848797 NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041
JBrowse link
G Cox6b1 cytochrome c oxidase subunit 6B1 affects expression ISO Isoniazid affects the expression of COX6B1 mRNA CTD PMID:24848797 NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
JBrowse link
G Cox7a2 cytochrome c oxidase subunit 7A2 affects expression ISO Isoniazid affects the expression of COX7A2 mRNA CTD PMID:24848797 NCBI chr 8:80,716,824...80,720,922 JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A affects expression ISO Isoniazid affects the expression of CPT1A mRNA CTD PMID:24848797 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases secretion ISO Isoniazid results in increased secretion of CXCL10 protein CTD PMID:28444390 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions
decreases expression
EXP [Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA]
Isoniazid results in decreased expression of CYB5A mRNA
CTD PMID:28619387 NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 increases expression EXP Isoniazid results in increased expression of CYP27A1 mRNA CTD PMID:32673658 NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity
multiple interactions
ISO Isoniazid results in decreased activity of CYP2C8 protein
torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]
CTD PMID:15304522
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 affects response to substance
increases response to substance
multiple interactions
increases activity
increases expression
increases metabolic processing
ISO
EXP
CYP2E1 gene polymorphism affects the susceptibility to Isoniazid; CYP2E1 gene SNP affects the susceptibility to Isoniazid
CYP2E1 protein results in increased susceptibility to Isoniazid
GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
Isoniazid results in increased activity of CYP2E1 protein
Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]
Isoniazid results in increased expression of CYP2E1; Isoniazid results in increased expression of CYP2E1 mRNA; Isoniazid results in increased expression of CYP2E1 protein
2-(allylthio)pyrazine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Isoniazid results in increased activity of CYP2E1 protein] which results in increased metabolism of 4-dichlorobenzene; [Isoniazid results in increased expression of CYP2E1] which results in increased metabolism of Acetaminophen; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Isoniazid inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine]; Isoniazid results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; Thiram inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Tiopronin inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]
CYP2E1 protein results in increased metabolism of Isoniazid
CTD PMID:3113478 PMID:7710944 PMID:8074729 PMID:9051121 PMID:9065729 More... NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
decreases activity
increases response to substance
EXP
ISO
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; [SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]
Isoniazid results in decreased activity of CYP3A4 protein
CYP3A4 protein results in increased susceptibility to Isoniazid
CTD PMID:15005856 PMID:15304522 PMID:19501153 PMID:21540358 PMID:27919644 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 increases expression
increases activity
multiple interactions
EXP Isoniazid results in increased expression of CYP3A23-3A1 mRNA
Isoniazid results in increased activity of CYP3A23-3A1 protein
diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP3A23-3A1 protein]
CTD PMID:12883083 PMID:26880746 NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
increases expression
EXP
ISO
[Lipopolysaccharides co-treated with Isoniazid] results in increased expression of CYP7A1 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA]
[Isoniazid co-treated with Vitamin B 6] results in increased expression of CYP7A1 mRNA
CTD PMID:25331106 PMID:32673658 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
decreases expression
EXP
ISO
Isoniazid results in increased expression of DDIT3 mRNA
Isoniazid results in decreased expression of DDIT3 mRNA
CTD PMID:12883083 PMID:30008028 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Depp1 DEPP1, autophagy regulator increases expression ISO Isoniazid results in increased expression of DEPP1 mRNA CTD PMID:17175557 NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
JBrowse link
G Epx eosinophil peroxidase increases oxidation
multiple interactions
ISO EPX protein results in increased oxidation of Isoniazid
[EPX protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD
CTD PMID:30922765 NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
JBrowse link
G Fech ferrochelatase decreases expression ISO Isoniazid results in decreased expression of FECH protein CTD PMID:27438535 PMID:30517741 NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha decreases expression EXP Isoniazid results in decreased expression of GADD45A mRNA CTD PMID:20623750 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase increases expression EXP Isoniazid results in increased expression of GAPDH mRNA CTD PMID:12883083 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
decreases expression
ISO
EXP
Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA]
Isoniazid results in increased expression of GCLC mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLC mRNA]
Isoniazid results in decreased expression of GCLC mRNA
CTD PMID:24128855 PMID:33121995 PMID:33771660 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit decreases expression
increases expression
multiple interactions
ISO
EXP
Isoniazid results in decreased expression of GCLM mRNA
Isoniazid results in increased expression of GCLM mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLM mRNA]
CTD PMID:30008028 PMID:33121995 PMID:33771660 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions
increases expression
EXP chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP mRNA]; chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP protein]
Isoniazid results in increased expression of GFAP mRNA; Isoniazid results in increased expression of GFAP protein
CTD PMID:33121995 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions EXP [Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GGT1 protein CTD PMID:25331106 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
JBrowse link
G Gpt glutamic--pyruvic transaminase increases activity
multiple interactions
increases expression
EXP
ISO
Isoniazid results in increased activity of GPT protein
Quercetin inhibits the reaction [Isoniazid results in increased expression of GPT protein]
[Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GPT protein; Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]; silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]]
CTD PMID:25331106 PMID:28619387 PMID:31332904 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression EXP Isoniazid results in increased expression of GSTA2 mRNA CTD PMID:12883083 NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions
decreases response to substance
ISO GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
GSTM1 protein results in decreased susceptibility to Isoniazid
CTD PMID:28762043 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
JBrowse link
G Gstp1 glutathione S-transferase pi 1 decreases expression EXP Isoniazid results in decreased expression of GSTP1 mRNA CTD PMID:20623750 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gstt1 glutathione S-transferase theta 1 multiple interactions ISO GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide] CTD PMID:18397238 PMID:20485159 NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 affects expression EXP Isoniazid affects the expression of HAVCR1 mRNA CTD PMID:20623750 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] CTD PMID:23764483 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
decreases expression
ISO
EXP
Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]
Isoniazid results in increased expression of HMOX1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA]
Isoniazid results in decreased expression of HMOX1 mRNA
CTD PMID:24128855 PMID:33121995 PMID:33771660 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hmox2 heme oxygenase 2 increases expression EXP Isoniazid results in increased expression of HMOX2 mRNA CTD PMID:12883083 NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
JBrowse link
G Hprt1 hypoxanthine phosphoribosyltransferase 1 increases expression EXP Isoniazid results in increased expression of HPRT1 mRNA CTD PMID:12883083 NCBI chr  X:132,736,175...132,768,149
Ensembl chr  X:132,736,096...132,768,154
JBrowse link
G Ifng interferon gamma increases secretion ISO Isoniazid results in increased secretion of IFNG protein CTD PMID:28444390 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il10 interleukin 10 increases secretion ISO Isoniazid results in increased secretion of IL10 protein CTD PMID:28444390 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il12a interleukin 12A increases secretion ISO Isoniazid results in increased secretion of IL12A protein CTD PMID:28444390 NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
JBrowse link
G Il12b interleukin 12B increases secretion ISO Isoniazid results in increased secretion of IL12B protein CTD PMID:28444390 NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
JBrowse link
G Il17a interleukin 17A increases secretion ISO Isoniazid results in increased secretion of IL17A protein CTD PMID:28444390 NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
JBrowse link
G Il1a interleukin 1 alpha increases secretion
increases expression
ISO Isoniazid results in increased secretion of IL1A protein
Isoniazid results in increased expression of IL1A mRNA
CTD PMID:28444390 PMID:32816093 NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
JBrowse link
G Il1b interleukin 1 beta increases secretion
multiple interactions
increases expression
ISO
EXP
Isoniazid results in increased secretion of IL1B protein
chrysin inhibits the reaction [Isoniazid results in increased expression of IL1B mRNA]
CTD PMID:28444390 PMID:32816093 PMID:33121995 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il24 interleukin 24 increases expression ISO Isoniazid results in increased expression of IL24 mRNA CTD PMID:32816093 NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions
increases secretion
ISO
EXP
Isoniazid results in increased expression of IL6 protein
Isoniazid results in increased expression of IL6 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of IL6 mRNA]
Isoniazid results in increased secretion of IL6 protein
CTD PMID:19575532 PMID:28444390 PMID:33121995 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Inhbe inhibin subunit beta E increases expression ISO Isoniazid results in increased expression of INHBE mRNA CTD PMID:17175557 NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
JBrowse link
G Izumo1r IZUMO1 receptor, JUNO decreases expression ISO Isoniazid results in decreased expression of IZUMO1R protein CTD PMID:33771660 NCBI chr 8:11,744,383...11,746,872
Ensembl chr 8:11,725,863...11,748,465
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 decreases expression ISO Isoniazid results in decreased expression of KEAP1 mRNA CTD PMID:33771660 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Lamp1 lysosomal-associated membrane protein 1 affects response to substance ISO LAMP1 affects the susceptibility to Isoniazid CTD PMID:24848797 NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
JBrowse link
G Lcn2 lipocalin 2 increases expression EXP Isoniazid results in increased expression of LCN2 mRNA CTD PMID:20623750 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
JBrowse link
G Map2 microtubule-associated protein 2 affects expression ISO Isoniazid affects the expression of MAP2 mRNA CTD PMID:22131109 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
multiple interactions
ISO Isoniazid results in decreased phosphorylation of MAPK1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]
CTD PMID:31332904 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein] CTD PMID:31332904 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 increases expression ISO Isoniazid results in increased expression of MGST1 mRNA CTD PMID:33771660 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
JBrowse link
G Mir106b microRNA 106b decreases expression EXP Isoniazide decreased expression of miR106b miRNA in the liver RGD PMID:29554950 RGD:15042854 NCBI chr12:17,043,344...17,043,425
Ensembl chr12:17,043,344...17,043,425
JBrowse link
G Mpo myeloperoxidase multiple interactions
increases oxidation
ISO [[MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals] which results in increased chemical synthesis of isonicotinyl-NAD; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD CTD PMID:26867495 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Mt-co3 mitochondrially encoded cytochrome c oxidase III increases expression EXP Isoniazid results in increased expression of COX3 mRNA CTD PMID:12883083 Ensembl chr MT:8,599...9,382 JBrowse link
G Muc1 mucin 1, cell surface associated increases expression ISO Isoniazid results in increased expression of MUC1 mRNA CTD PMID:30008028 NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
JBrowse link
G Nat2 N-acetyltransferase 2 increases acetylation
multiple interactions
decreases expression
decreases acetylation
increases metabolic processing
affects metabolic processing
affects response to substance
ISO
EXP
NAT2 protein polymorphism results in increased acetylation of Isoniazid; NAT2 protein results in increased acetylation of Isoniazid
[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]
Isoniazid results in decreased expression of NAT2 mRNA
[NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid; [NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine
NAT2 protein results in increased metabolism of Isoniazid
NAT2 protein affects the metabolism of Isoniazid; NAT2 protein polymorphism affects the metabolism of Isoniazid
NAT2 gene polymorphism affects the susceptibility to Isoniazid; NAT2 gene SNP affects the susceptibility to Isoniazid
CTD PMID:11379777 PMID:11915035 PMID:15546075 PMID:15565348 PMID:15618686 More... NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
JBrowse link
G Ncr3lg1 natural killer cell cytotoxicity receptor 3 ligand 1 increases expression ISO Isoniazid results in increased expression of NCR3LG1 mRNA; Isoniazid results in increased expression of NCR3LG1 protein CTD PMID:32060585 NCBI chr 1:96,565,664...96,581,825 JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 affects expression ISO Isoniazid affects the expression of NDUFA1 mRNA CTD PMID:24848797 NCBI chr  X:116,424,223...116,427,875
Ensembl chr  X:116,424,223...116,428,633
JBrowse link
G Ndufa10 NADH:ubiquinone oxidoreductase subunit A10 affects expression ISO Isoniazid affects the expression of NDUFA10 mRNA CTD PMID:24848797 NCBI chr 9:93,007,034...93,041,825
Ensembl chr 9:93,007,042...93,042,560
JBrowse link
G Ndufa12 NADH:ubiquinone oxidoreductase subunit A12 affects expression ISO Isoniazid affects the expression of NDUFA12 mRNA CTD PMID:24848797 NCBI chr 7:28,771,330...28,798,316
Ensembl chr 7:28,771,330...28,798,315
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 affects expression ISO Isoniazid affects the expression of NDUFA13 mRNA CTD PMID:24848797 NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
JBrowse link
G Ndufa4 NDUFA4, mitochondrial complex associated affects expression ISO Isoniazid affects the expression of NDUFA4 mRNA CTD PMID:24848797 NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
JBrowse link
G Ndufa5 NADH:ubiquinone oxidoreductase subunit A5 affects expression ISO Isoniazid affects the expression of NDUFA5 mRNA CTD PMID:24848797 NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
JBrowse link
G Ndufa8 NADH:ubiquinone oxidoreductase subunit A8 affects expression ISO Isoniazid affects the expression of NDUFA8 mRNA CTD PMID:24848797 NCBI chr 3:19,386,063...19,402,093
Ensembl chr 3:19,386,065...19,402,071
JBrowse link
G Ndufa9 NADH:ubiquinone oxidoreductase subunit A9 affects expression ISO Isoniazid affects the expression of NDUFA9 mRNA CTD PMID:24848797 NCBI chr 4:159,659,242...159,688,034
Ensembl chr 4:159,659,242...159,688,018
JBrowse link
G Ndufab1 NADH:ubiquinone oxidoreductase subunit AB1 affects expression ISO Isoniazid affects the expression of NDUFAB1 mRNA CTD PMID:24848797 NCBI chr 1:176,644,696...176,658,131
Ensembl chr 1:176,644,703...176,658,099
JBrowse link
G Ndufb10 NADH:ubiquinone oxidoreductase subunit B10 affects expression ISO Isoniazid affects the expression of NDUFB10 mRNA CTD PMID:24848797 NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442
JBrowse link
G Ndufb2 NADH:ubiquinone oxidoreductase subunit B2 affects expression ISO Isoniazid affects the expression of NDUFB2 mRNA CTD PMID:24848797 NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851
JBrowse link
G Ndufb3 NADH:ubiquinone oxidoreductase subunit B3 affects expression ISO Isoniazid affects the expression of NDUFB3 mRNA CTD PMID:24848797 NCBI chr 9:60,129,240...60,139,452
Ensembl chr 9:60,129,154...60,139,446
JBrowse link
G Ndufb5 NADH:ubiquinone oxidoreductase subunit B5 affects expression ISO Isoniazid affects the expression of NDUFB5 mRNA CTD PMID:24848797 NCBI chr 2:115,519,248...115,533,589
Ensembl chr 2:115,519,154...115,533,589
JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 affects expression ISO Isoniazid affects the expression of NDUFB6 mRNA CTD PMID:24848797 NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181
JBrowse link
G Ndufb7 NADH:ubiquinone oxidoreductase subunit B7 affects expression ISO Isoniazid affects the expression of NDUFB7 mRNA CTD PMID:24848797 NCBI chr19:24,568,241...24,572,579
Ensembl chr19:24,568,241...24,572,579
JBrowse link
G Ndufs1 NADH:ubiquinone oxidoreductase core subunit S1 affects expression ISO Isoniazid affects the expression of NDUFS1 mRNA CTD PMID:24848797 NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893
JBrowse link
G Ndufs2 NADH:ubiquinone oxidoreductase core subunit S2 affects expression ISO Isoniazid affects the expression of NDUFS2 mRNA CTD PMID:24848797 NCBI chr13:83,654,402...83,671,474
Ensembl chr13:83,654,406...83,671,420
JBrowse link
G Ndufs3 NADH:ubiquinone oxidoreductase core subunit S3 affects expression ISO Isoniazid affects the expression of NDUFS3 mRNA CTD PMID:24848797 NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824
JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 affects expression ISO Isoniazid affects the expression of NDUFS4 mRNA CTD PMID:24848797 NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
JBrowse link
G Ndufs8 NADH:ubiquinone oxidoreductase core subunit S8 affects expression ISO Isoniazid affects the expression of NDUFS8 mRNA CTD PMID:24848797 NCBI chr 1:201,140,585...201,144,573
Ensembl chr 1:201,140,585...201,144,511
JBrowse link
G Ndufv1 NADH:ubiquinone oxidoreductase core subunit V1 affects expression ISO Isoniazid affects the expression of NDUFV1 mRNA CTD PMID:24848797 NCBI chr 1:201,300,365...201,305,461
Ensembl chr 1:201,299,985...201,305,466
JBrowse link
G Ndufv2 NADH:ubiquinone oxidoreductase core subunit V2 affects expression ISO Isoniazid affects the expression of NDUFV2 mRNA CTD PMID:24848797 NCBI chr 9:105,690,454...105,710,669
Ensembl chr 9:105,690,455...105,710,713
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases activity
increases expression
multiple interactions
ISO
EXP
Isoniazid results in increased activity of NFE2L2 protein
Isoniazid results in increased expression of NFE2L2 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NFE2L2 mRNA]
CTD PMID:30203046 PMID:33121995 PMID:33771660 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases expression
multiple interactions
EXP Isoniazid results in increased expression of NFKB1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NFKB1 mRNA]
CTD PMID:33121995 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression
decreases expression
ISO
EXP
Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]
Isoniazid results in increased expression of NQO1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NQO1 mRNA]
Isoniazid results in decreased expression of NQO1 mRNA
CTD PMID:24128855 PMID:28444390 PMID:33121995 PMID:33771660 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 decreases expression
multiple interactions
EXP
ISO
Isoniazid results in decreased expression of NR0B2 mRNA
[Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR0B2 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR0B2 mRNA]
CTD PMID:32673658 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
decreases expression
EXP
ISO
[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 mRNA; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 protein; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR1H4 mRNA]
[Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR1H4 mRNA
isoniazide decreases expression of nr1h4 protein in rat liver
CTD PMID:25331106 PMID:32673658 PMID:30068870 RGD:15042870 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO Isoniazid results in increased activity of NR1I3 protein CTD PMID:30203046 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
G Nrf1 nuclear respiratory factor 1 multiple interactions
decreases expression
ISO acadesine inhibits the reaction [Isoniazid results in decreased expression of NRF1 protein] CTD PMID:28556920 NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator increases expression ISO Isoniazid results in increased expression of NUPR1 mRNA CTD PMID:17175557 NCBI chr 1:181,213,292...181,215,327 JBrowse link
G Ogdh oxoglutarate dehydrogenase affects expression ISO Isoniazid affects the expression of OGDH mRNA CTD PMID:24848797 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Park7 Parkinsonism associated deglycase affects expression ISO Isoniazid affects the expression of PARK7 mRNA CTD PMID:24848797 NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
JBrowse link
G Pid1 phosphotyrosine interaction domain containing 1 increases expression ISO Isoniazid results in increased expression of PID1 mRNA CTD PMID:32816093 NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
JBrowse link
G Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 increases expression ISO Isoniazid results in increased expression of PLOD2 mRNA CTD PMID:15997088 NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions
decreases expression
EXP [Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA]
Isoniazid results in decreased expression of POR mRNA
CTD PMID:28619387 NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases activity ISO Isoniazid results in increased activity of PPARA protein CTD PMID:30203046 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO Isoniazid results in decreased expression of PPARG mRNA
Isoniazid results in decreased expression of PPARG mRNA; Isoniazid results in decreased expression of PPARG protein
CTD PMID:24128855 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression
multiple interactions
ISO Isoniazid results in decreased expression of PPARGC1A protein
acadesine inhibits the reaction [Isoniazid results in decreased expression of PPARGC1A protein]
CTD PMID:28556920 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Psen1 presenilin 1 affects expression ISO Isoniazid affects the expression of PSEN1 mRNA CTD PMID:24848797 NCBI chr 6:103,323,014...103,375,088
Ensembl chr 6:103,323,120...103,371,650
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO Isoniazid results in increased expression of PTGS2 mRNA CTD PMID:32816093 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Sdha succinate dehydrogenase complex flavoprotein subunit A affects expression ISO Isoniazid affects the expression of SDHA mRNA CTD PMID:24848797 NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535
JBrowse link
G Sdhb succinate dehydrogenase complex iron sulfur subunit B affects expression ISO Isoniazid affects the expression of SDHB mRNA CTD PMID:24848797 NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
JBrowse link
G Sdhd succinate dehydrogenase complex subunit D affects expression ISO Isoniazid affects the expression of SDHD mRNA CTD PMID:24848797 NCBI chr 8:50,944,717...50,954,298
Ensembl chr 8:50,944,704...50,954,238
JBrowse link
G Sfn stratifin decreases expression ISO Isoniazid results in decreased expression of SFN mRNA CTD PMID:30008028 Ensembl chr 5:145,826,201...145,831,314 JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
ISO acadesine inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]; Quercetin inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein] CTD PMID:28556920 PMID:31332904 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Slc10a1 solute carrier family 10 member 1 decreases expression
multiple interactions
EXP Isoniazid results in decreased expression of SLC10A1 mRNA
obeticholic acid promotes the reaction [Isoniazid results in decreased expression of SLC10A1 mRNA]
CTD PMID:32673658 NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
JBrowse link
G Slc11a1 solute carrier family 11 member 1 affects expression EXP Isoniazid affects the expression of SLC11A1 mRNA CTD PMID:20623750 NCBI chr 9:75,957,193...75,968,115
Ensembl chr 9:75,957,316...75,968,101
JBrowse link
G Slc7a5 solute carrier family 7 member 5 decreases expression ISO Isoniazid results in decreased expression of SLC7A5 mRNA CTD PMID:30008028 NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
JBrowse link
G Slco1a1 solute carrier organic anion transporter family, member 1a1 decreases expression EXP Isoniazid results in decreased expression of SLCO1B1 mRNA CTD PMID:32673658 NCBI chr 4:174,877,045...174,950,857
Ensembl chr 4:174,876,593...174,950,873
JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO Isoniazid results in increased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
JBrowse link
G Sod1 superoxide dismutase 1 increases expression ISO Isoniazid results in increased expression of SOD1 mRNA CTD PMID:33771660 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
affects expression
EXP
ISO
[SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid
Isoniazid affects the expression of SOD2 mRNA
CTD PMID:19501153 PMID:24848797 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Spp1 secreted phosphoprotein 1 affects expression
decreases expression
EXP
ISO
Isoniazid affects the expression of SPP1 mRNA
Isoniazid results in decreased expression of SPP1 mRNA
CTD PMID:20623750 PMID:30008028 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO Isoniazid results in increased expression of SRXN1 mRNA CTD PMID:28444390 NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
JBrowse link
G Surf1 SURF1, cytochrome c oxidase assembly factor affects expression ISO Isoniazid affects the expression of SURF1 mRNA CTD PMID:24848797 NCBI chr 3:10,241,793...10,244,686
Ensembl chr 3:10,241,837...10,263,315
JBrowse link
G Tf transferrin increases expression EXP Isoniazid results in increased expression of TF mRNA CTD PMID:12883083 NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
JBrowse link
G Tmprss2 transmembrane serine protease 2 affects expression ISO Isoniazid affects the expression of TMPRSS2 mRNA CTD PMID:32808185 NCBI chr11:36,934,306...36,973,779
Ensembl chr11:36,934,306...36,973,715
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
increases secretion
EXP
ISO
Isoniazid results in increased expression of TNF protein
[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein; chrysin inhibits the reaction [Isoniazid results in increased expression of TNF protein]; Isoniazid promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein]
Isoniazid results in increased secretion of TNF protein
CTD PMID:25331106 PMID:28444390 PMID:28619387 PMID:33121995 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tpo thyroid peroxidase decreases activity EXP Isoniazid results in decreased activity of TPO protein CTD PMID:26884060 NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
JBrowse link
G Trak1 trafficking kinesin protein 1 affects expression ISO Isoniazid affects the expression of TRAK1 mRNA CTD PMID:24848797 NCBI chr 8:120,984,445...121,139,357
Ensembl chr 8:120,984,431...121,139,367
JBrowse link
G Trib3 tribbles pseudokinase 3 increases expression ISO Isoniazid results in increased expression of TRIB3 mRNA CTD PMID:30008028 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
JBrowse link
G Txn2 thioredoxin 2 affects expression ISO Isoniazid affects the expression of TXN2 mRNA CTD PMID:24848797 NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression ISO Isoniazid results in increased expression of TXNRD1 mRNA CTD PMID:28444390 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
JBrowse link
G Txnrd2 thioredoxin reductase 2 affects expression ISO Isoniazid affects the expression of TXNRD2 mRNA CTD PMID:24848797 NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156
JBrowse link
G Uqcrb ubiquinol-cytochrome c reductase binding protein affects expression ISO Isoniazid affects the expression of UQCRB mRNA CTD PMID:24848797 NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150
JBrowse link
G Uqcrc2 ubiquinol cytochrome c reductase core protein 2 affects expression ISO Isoniazid affects the expression of UQCRC2 mRNA CTD PMID:24848797 NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
JBrowse link
isonicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bglap bone gamma-carboxyglutamate protein increases expression EXP
ISO
isonicotinamide results in increased expression of BGLAP mRNA CTD PMID:16813520 PMID:21745208 NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression
increases expression
ISO isonicotinamide results in decreased expression of FABP4 mRNA
isonicotinamide results in increased expression of FABP4 mRNA
CTD PMID:16813520 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO isonicotinamide results in decreased expression of PPARG mRNA CTD PMID:16813520 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Runx2 RUNX family transcription factor 2 increases expression ISO isonicotinamide results in increased expression of RUNX2 mRNA CTD PMID:21745208 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Sirt1 sirtuin 1 increases activity
increases expression
ISO isonicotinamide results in increased activity of SIRT1 protein
isonicotinamide results in increased expression of SIRT1 mRNA
CTD PMID:21745208 NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Sp7 Sp7 transcription factor increases expression ISO isonicotinamide results in increased expression of SP7 mRNA CTD PMID:21745208 NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression ISO isonicotinamide results in increased expression of SPP1 mRNA CTD PMID:21745208 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B increases expression ISO isonicotinamide results in increased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
N'-acetylisoniazid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mpo myeloperoxidase increases oxidation ISO MPO protein results in increased oxidation of (N)1-acetylisoniazid CTD PMID:26867495 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
N-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
CTD PMID:27469509 NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of N-methylnicotinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
N-ribosylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions
increases oxidation
ISO [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
CTD PMID:20399199 PMID:29281794 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
JBrowse link
nicorandil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP binding cassette subfamily C member 9 increases activity ISO Nicorandil results in increased activity of ABCC9 protein CTD PMID:22622455 NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
JBrowse link
G Agt angiotensinogen multiple interactions ISO Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] CTD PMID:22622455 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein] CTD PMID:31376360 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] CTD PMID:31376360 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Cat catalase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] CTD PMID:31376360 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ctsd cathepsin D multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:11829124 PMID:14499179 NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
JBrowse link
G Gusb glucuronidase, beta multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:11829124 PMID:14499179 NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:31376360 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression EXP Nicorandil results in decreased expression of HMOX1 protein CTD PMID:22622455 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] CTD PMID:31376360 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] CTD PMID:31376360 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] CTD PMID:31376360 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] CTD PMID:31376360 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP Nicorandil results in increased expression of SOD2 protein CTD PMID:22622455 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] CTD PMID:31376360 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein] CTD PMID:31376360 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
decreases expression
ISO
EXP
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein
CTD PMID:22622455 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
JBrowse link
nicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases phosphorylation
ISO
EXP
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein
CTD PMID:18482975 PMID:19071085 PMID:21212096 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases secretion
multiple interactions
ISO
EXP
Niacinamide results in increased secretion of ADIPOQ protein
[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
CTD PMID:17452443 PMID:21439372 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Ago2 argonaute RISC catalytic component 2 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] CTD PMID:24792773 NCBI chr 7:105,018,202...105,105,120
Ensembl chr 7:105,029,120...105,104,974
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA CTD PMID:18420994 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] CTD PMID:25478867 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
EXP
ISO
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX mRNA]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
CTD PMID:16168987 PMID:16998810 PMID:22164206 PMID:25478867 PMID:26712469 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA
CTD PMID:26712469 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
CTD PMID:25472572 PMID:25478867 PMID:26712469 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA
CTD PMID:25472572 PMID:26712469 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] CTD PMID:24792773 NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased activity of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CTD PMID:16505238 PMID:22164206 PMID:24040102 PMID:24962570 PMID:25478867 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
CTD PMID:16505238 PMID:25478867 PMID:26712469 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] CTD PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 More... NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Niacinamide results in decreased expression of CCL2 protein CTD PMID:14627904 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Niacinamide results in increased expression of CCL20 mRNA CTD PMID:22385246 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] CTD PMID:22717288 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression
ISO
EXP
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein
CTD PMID:12782109 PMID:22561310 PMID:25478867 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression
multiple interactions
EXP Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CTD PMID:22561310 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] CTD PMID:24792773 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases activity
multiple interactions
ISO Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
CTD PMID:24962570 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
CTD PMID:16813520 PMID:25707573 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
increases expression
EXP Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] CTD PMID:23422569 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:27919644 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Defb4 defensin beta 4 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA CTD PMID:24894820 NCBI chr16:70,650,472...70,653,665
Ensembl chr16:70,650,472...70,653,665
JBrowse link
G Dicer1 dicer 1 ribonuclease III multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] CTD PMID:24792773 NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] CTD PMID:21232033 NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] CTD PMID:24792773 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
CTD PMID:19928762 PMID:20169165 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor increases abundance
multiple interactions
ISO ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CTD PMID:25440059 NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
JBrowse link
G F3 coagulation factor III, tissue factor decreases expression ISO Niacinamide results in decreased expression of F3 protein CTD PMID:14627904 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] CTD PMID:16168987 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO
EXP
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
CTD PMID:16917544 PMID:20181797 PMID:26712469 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein CTD PMID:23022493 PMID:25472572 PMID:26712469 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA] CTD PMID:16917544 NCBI chr10:86,307,400...86,318,766 JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] CTD PMID:19059388 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Gcg glucagon multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] CTD PMID:23466488 NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] CTD PMID:21439372 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression
EXP Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
JBrowse link
G Glo1 glyoxalase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] CTD PMID:21439372 NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein] CTD PMID:32894639 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] CTD PMID:20307516 PMID:21439372 PMID:32894639 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] CTD PMID:21439372 NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions EXP [Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein] CTD PMID:32894639 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
JBrowse link
G Gys2 glycogen synthase 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] CTD PMID:19059388 NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] CTD PMID:19647726 NCBI chr10:15,323,830...15,324,677 JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] CTD PMID:24792773 NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] CTD PMID:20696151 PMID:21212096 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] CTD PMID:21439372 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] CTD PMID:24145604 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] CTD PMID:16917544 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Il18 interleukin 18 multiple interactions EXP [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA CTD PMID:28322830 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
CTD PMID:12727023 PMID:20307516 PMID:21439372 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins2 insulin 2 multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] CTD PMID:16168987 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] CTD PMID:21439372 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Klf4 Kruppel like factor 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA] CTD PMID:31081965 NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] CTD PMID:20696151 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] CTD PMID:20696151 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] CTD PMID:16505238 NCBI chr 7:107,432,292...107,435,061
Ensembl chr 7:107,433,605...107,434,690
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] CTD PMID:16168987 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Niacinamide results in increased expression of MDM2 mRNA CTD PMID:16998810 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Mir3545 microRNA 3545 multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] CTD PMID:24792773 NCBI chr 6:131,199,542...131,199,656
Ensembl chr 6:131,199,542...131,199,656
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
ISO Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Msra methionine sulfoxide reductase A multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] CTD PMID:23022493 NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
CTD PMID:19928762 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] CTD PMID:22028816 PMID:24792773 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nabp2 nucleic acid binding protein 2 decreases ubiquitination
increases acetylation
multiple interactions
ISO Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
CTD PMID:26170237 NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
CTD PMID:26712469 PMID:32298659 NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]
CTD PMID:22539994 NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] CTD PMID:23891692 NCBI chr  X:116,424,223...116,427,875
Ensembl chr  X:116,424,223...116,428,633
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] CTD PMID:23891692 NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] CTD PMID:23891692 NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] CTD PMID:21439372 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP [Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA] CTD PMID:32894639 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] CTD PMID:23735732 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
EXP GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] CTD PMID:23422569 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO [Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA CTD PMID:20505214 NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions ISO Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] CTD PMID:18381761 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
decreases activity
EXP
ISO
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased cleavage of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein
CTD PMID:16168987 PMID:19288225 PMID:22164206 PMID:26712469 PMID:29143419 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] CTD PMID:20181797 NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
JBrowse link
G Pdp1 pyruvate dehydrogenase phosphatase catalytic subunit 1 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] CTD PMID:20181797 NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein CTD PMID:29143419 NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions ISO Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] CTD PMID:22028816 NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] CTD PMID:22539994 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases acetylation
multiple interactions
ISO
EXP
Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
CTD PMID:19071085 PMID:23422569 PMID:23891692 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] CTD PMID:18482975 NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] CTD PMID:18482975 NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
CTD PMID:24145604 PMID:24962570 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Pygl glycogen phosphorylase L multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
Niacinamide inhibits the reaction [resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
CTD PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 More... NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein CTD PMID:20169165 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression
multiple interactions
increases expression
ISO
EXP
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA
CTD PMID:16813520 PMID:22539994 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
ISO Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
CTD PMID:21778425 PMID:24557422 NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
decreases activity
ISO
EXP
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
CTD PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 More... NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
JBrowse link
G Sirt2 sirtuin 2 decreases activity
multiple interactions
ISO Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein
CTD PMID:17341628 PMID:26712469 NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein CTD PMID:26712469 NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA] CTD PMID:32298659 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of Niacinamide CTD PMID:21561886 NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
JBrowse link
G Snap23 synaptosome associated protein 23 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] CTD PMID:25999625 NCBI chr 3:107,514,088...107,546,177 JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein] CTD PMID:31081965 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
CTD PMID:23891692 PMID:25472572 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
CTD PMID:24962570 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] CTD PMID:23319015 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Stx4 syntaxin 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] CTD PMID:25999625 NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA
CTD PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B decreases expression ISO Niacinamide results in decreased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
JBrowse link
G Tnfsf11 TNF superfamily member 11 decreases expression ISO Niacinamide results in decreased expression of TNFSF11 mRNA CTD PMID:16813520 NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein
CTD PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions ISO Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] CTD PMID:16366736 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] CTD PMID:25999625 NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809
JBrowse link
nicotinic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions
increases expression
decreases expression
ISO
EXP
[Chromium co-treated with Niacin] results in decreased expression of ABCA1 mRNA
Niacin results in increased expression of ABCA1 mRNA
Niacin results in decreased expression of ABCA1 protein
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin results in increased expression of ABCA1 mRNA]; [[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein; ABCA1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL]; PPARG protein promotes the reaction [Niacin results in increased expression of ABCA1 mRNA]
CTD PMID:15037193 PMID:18602814 PMID:19797938 PMID:19878707 PMID:20303128 More... NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression
multiple interactions
increases expression
EXP
ISO
Niacin results in decreased expression of ABCG1 protein
[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol; ABCG1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL]; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]
CTD PMID:19878707 PMID:20448206 PMID:21317532 NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
JBrowse link
G Ace angiotensin I converting enzyme decreases activity EXP Niacin results in decreased activity of ACE protein CTD PMID:18374418 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Ache acetylcholinesterase multiple interactions ISO [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of ACHE protein]; Niacin inhibits the reaction [Rotenone results in increased expression of ACHE protein] CTD PMID:31820278 NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Acmsd aminocarboxymuconate semialdehyde decarboxylase affects abundance
multiple interactions
EXP ACMSD protein affects the abundance of Niacin
[Diethylhexyl Phthalate results in decreased activity of ACMSD protein] which results in increased abundance of Niacin; Dibutyl Phthalate affects the reaction [ACMSD protein affects the abundance of Niacin]
CTD PMID:12036039 NCBI chr13:39,200,486...39,244,337
Ensembl chr13:39,200,314...39,245,209
JBrowse link
G Adam17 ADAM metallopeptidase domain 17 increases expression EXP Niacin results in increased expression of ADAM17 protein CTD PMID:19223914 NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases expression
multiple interactions
ISO
EXP
Niacin results in increased expression of ADIPOQ mRNA; Niacin results in increased expression of ADIPOQ protein
HCAR2 protein promotes the reaction [Niacin results in increased expression of ADIPOQ protein]
Niacin promotes the reaction [ADIPOQ protein binds to ADIPOQ protein]
CTD PMID:16887123 PMID:16979396 PMID:17996241 PMID:18249215 PMID:19131065 More... NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Adora2a adenosine A2a receptor multiple interactions ISO [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of ADORA2A mRNA]; Niacin inhibits the reaction [Rotenone results in increased expression of ADORA2A mRNA] CTD PMID:31820278 NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
JBrowse link
G Agt angiotensinogen multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species]
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of AGT protein]; Niacin inhibits the reaction [Rotenone results in increased expression of AGT protein]
Niacin results in decreased expression of AGT protein
CTD PMID:18374418 PMID:18550065 PMID:31820278 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Ahsg alpha-2-HS-glycoprotein multiple interactions ISO Niacin results in decreased expression of and results in decreased phosphorylation of AHSG protein CTD PMID:19405044 NCBI chr11:78,117,903...78,145,956 JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP [Niacin co-treated with Chromium] results in increased phosphorylation of AKT1 protein CTD PMID:19027847 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Angpt1 angiopoietin 1 increases expression ISO
EXP
Niacin results in increased expression of ANGPT1 mRNA CTD PMID:17557352 NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
JBrowse link
G Angpt2 angiopoietin 2 decreases expression ISO Niacin results in decreased expression of ANGPT2 mRNA CTD PMID:17557352 NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions
increases expression
ISO [Chromium co-treated with Niacin] results in increased expression of APOA1 mRNA; [Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein]
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]
Niacin results in increased expression of APOA1 protein
CTD PMID:11701466 PMID:12633795 PMID:12767421 PMID:15539964 PMID:17319473 More... NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
JBrowse link
G Apob apolipoprotein B multiple interactions
decreases expression
ISO [Niacin co-treated with Lovastatin] results in decreased expression of APOB protein; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein
Niacin results in decreased expression of APOB protein
CTD PMID:11701466 PMID:12633795 PMID:15539964 PMID:18471454 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
JBrowse link
G Arhgap8 Rho GTPase activating protein 8 increases expression EXP Niacin results in increased expression of ARHGAP8 mRNA CTD PMID:20303128 NCBI chr 7:115,842,223...115,902,094
Ensembl chr 7:115,850,654...115,902,093
JBrowse link
G Asph aspartate-beta-hydroxylase multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ASPH mRNA] CTD PMID:16940432 NCBI chr 5:22,603,879...22,814,107
Ensembl chr 5:22,603,486...22,813,876
JBrowse link
G Atp5f1b ATP synthase F1 subunit beta decreases expression ISO Niacin results in decreased expression of ATP5F1B protein CTD PMID:18316796 NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
JBrowse link
G Bdnf brain-derived neurotrophic factor increases expression EXP Niacin results in increased expression of BDNF protein CTD PMID:20671245 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Btc betacellulin multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of BTC mRNA] CTD PMID:16940432 NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased activity of CASP3 protein]; Niacin inhibits the reaction [Rotenone results in increased activity of CASP3 protein] CTD PMID:31820278 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casq1 calsequestrin 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of CASQ1 mRNA] CTD PMID:16940432 NCBI chr13:84,670,648...84,680,339
Ensembl chr13:84,670,649...84,680,339
JBrowse link
G Cat catalase multiple interactions
increases expression
EXP [Niacin co-treated with Chromium] results in increased activity of CAT protein
Niacin results in increased expression of CAT protein
CTD PMID:16931439 PMID:19420110 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cav1 caveolin 1 multiple interactions EXP [Niacin co-treated with Chromium] inhibits the reaction [CAV1 protein binds to NOS3 protein]; [Niacin co-treated with Chromium] results in decreased expression of CAV1 protein CTD PMID:19027847 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
JBrowse link
G Cav3 caveolin 3 multiple interactions EXP [Niacin co-treated with Chromium] promotes the reaction [SLC2A4 protein binds to CAV3 protein]; [Niacin co-treated with Chromium] results in increased expression of CAV3 protein CTD PMID:19027847 NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression
multiple interactions
ISO
EXP
Niacin results in decreased expression of CCL2 protein
Niacin inhibits the reaction [TNF protein results in increased expression of CCL2 protein]
CTD PMID:18550065 PMID:19420110 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Cd36 CD36 molecule increases expression
decreases expression
ISO
EXP
Niacin results in increased expression of CD36 mRNA
Niacin results in decreased expression of CD36 protein
CTD PMID:19878707 PMID:24767308 NCBI chr 4:17,317,343...17,410,084 JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
EXP Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein] CTD PMID:17516866 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha increases expression ISO Niacin results in increased expression of CEBPA mRNA CTD PMID:19131065 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
decreases expression
ISO [Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]] which results in decreased expression of PTGS2 mRNA; Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]
Niacin results in decreased expression of CEBPB mRNA; Niacin results in decreased expression of CEBPB protein
CTD PMID:21236357 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression ISO Niacin results in increased expression of CEBPD mRNA CTD PMID:19131065 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
JBrowse link
G Cert1 ceramide transporter 1 multiple interactions ISO [Niacin results in decreased expression of and results in decreased activity of CERT1 protein] which results in increased abundance of Cholesterol, HDL; Niacin results in decreased expression of and results in decreased activity of CERT1 protein CTD PMID:18669886 NCBI chr 2:27,882,546...27,987,090
Ensembl chr 2:27,882,555...27,987,074
JBrowse link
G Chn2 chimerin 2 increases expression EXP Niacin results in increased expression of CHN2 mRNA CTD PMID:20303128 NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709
JBrowse link
G Cidea cell death-inducing DFFA-like effector a multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of CIDEA mRNA] CTD PMID:16940432 NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 decreases expression ISO Niacin results in decreased expression of CPT2 mRNA CTD PMID:19131065 NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
JBrowse link
G Crp C-reactive protein multiple interactions
decreases expression
ISO [resveratrol co-treated with pterostilbene co-treated with Quercetin co-treated with tocotrienol, delta co-treated with Niacin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of CRP protein]; Niacin inhibits the reaction [Rotenone results in increased expression of CRP protein]
CTD PMID:16950175 PMID:18420099 PMID:24319627 PMID:31820278 NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
JBrowse link
G Cst11 cystatin 11 increases expression EXP Niacin results in increased expression of CST11 mRNA CTD PMID:20303128 NCBI chr 3:136,211,414...136,214,138
Ensembl chr 3:136,211,414...136,214,138
JBrowse link
G Cst8 cystatin 8 increases expression EXP Niacin results in increased expression of CST8 mRNA CTD PMID:20303128 NCBI chr 3:136,244,586...136,255,412
Ensembl chr 3:136,244,636...136,251,273
JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression EXP Niacin results in decreased expression of CYBA protein CTD PMID:19420110 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Ddhd1 DDHD domain containing 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of DDHD1 mRNA] CTD PMID:16940432 NCBI chr15:18,824,389...18,891,036
Ensembl chr15:18,824,394...18,890,952
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions
decreases activity
ISO [Niacin results in decreased activity of DGAT2 protein] which results in decreased chemical synthesis of Triglycerides CTD PMID:15258194 NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
JBrowse link
G Dusp5 dual specificity phosphatase 5 increases expression EXP Niacin results in increased expression of DUSP5 mRNA CTD PMID:20303128 NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
JBrowse link
G Ecel1 endothelin converting enzyme-like 1 increases expression EXP Niacin results in increased expression of ECEL1 mRNA CTD PMID:20303128 NCBI chr 9:87,814,434...87,829,154
Ensembl chr 9:87,816,718...87,826,675
JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of EDNRB mRNA] CTD PMID:16940432 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
JBrowse link
G Egr2 early growth response 2 increases expression EXP Niacin results in increased expression of EGR2 mRNA CTD PMID:20303128 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A increases phosphorylation EXP Niacin results in increased phosphorylation of EIF2A protein CTD PMID:12837665 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions EXP Niacin results in decreased phosphorylation of and results in decreased activity of EIF4EBP1 protein CTD PMID:12837665 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Eno3 enolase 3 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ENO3 mRNA] CTD PMID:16940432 NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
JBrowse link
G F2r coagulation factor II (thrombin) receptor increases expression ISO Niacin results in increased expression of F2R protein CTD PMID:20539903 NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
JBrowse link
G Fabp1 fatty acid binding protein 1 increases expression EXP Niacin results in increased expression of FABP1 protein CTD PMID:19878707 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 protein; fluprostenol inhibits the reaction [Niacin results in increased expression of FABP4 mRNA] CTD PMID:21236357 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Fasn fatty acid synthase decreases expression ISO Niacin results in decreased expression of FASN mRNA CTD PMID:19131065 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Foxo1 forkhead box O1 multiple interactions EXP Niacin results in decreased phosphorylation of and results in increased activity of FOXO1 protein CTD PMID:20303128 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Gcg glucagon multiple interactions ISO [Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein; Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein] CTD PMID:838844 NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
JBrowse link
G Ggt1 gamma-glutamyltransferase 1 increases expression EXP Niacin results in increased expression of GGT1 mRNA CTD PMID:20303128 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
JBrowse link
G Gh1 growth hormone 1 multiple interactions ISO [Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein; Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein] CTD PMID:838844 NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO [INS1 protein co-treated with Niacin] results in increased activity of GPD1 protein CTD PMID:2523799 NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
JBrowse link
G Gpi glucose-6-phosphate isomerase multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of GPI1 mRNA] CTD PMID:16940432 NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
JBrowse link
G Hcar2 hydroxycarboxylic acid receptor 2 multiple interactions
affects activity
increases response to substance
affects binding
increases activity
ISO
EXP
[Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein; [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein]; Niacin binds to and affects the activity of HCAR2 protein; Niacin binds to and results in increased activity of HCAR2 protein
Niacin affects the activity of HCAR2 protein
HCAR2 protein results in increased susceptibility to Niacin
[[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [HCAR2 protein results in increased susceptibility to Niacin] which results in increased abundance of Dinoprostone; [HCAR2 protein results in increased susceptibility to Niacin] which results in increased abundance of Prostaglandin D2; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Cyclic AMP; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Triglycerides; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]; HCAR2 protein promotes the reaction [Niacin results in decreased abundance of Fatty Acids]; HCAR2 protein promotes the reaction [Niacin results in increased expression of ADIPOQ protein]; Niacin binds to and results in increased activity of HCAR2 protein
[Niacin analog binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; Niacin binds to and results in increased activity of HCAR2 protein
Niacin binds to HCAR2 protein
CTD PMID:12563315 PMID:15929991 PMID:16018973 PMID:16099840 PMID:16322797 More... NCBI chr12:32,726,334...32,727,416
Ensembl chr12:32,726,184...32,728,504
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression EXP Niacin results in decreased expression of HIF1A protein CTD PMID:18549825 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [[Niacin binds to Chromium] which co-treated with Cardiotonic Agents] results in increased expression of HMOX1 protein CTD PMID:16840737 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions EXP [[Niacin binds to Chromium] which co-treated with Cardiotonic Agents] results in increased expression of HSPB1 protein CTD PMID:16840737 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
[Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of ICAM1 mRNA]; [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of ICAM1 protein]
Niacin results in decreased expression of ICAM1 protein
CTD PMID:16916501 PMID:18622720 PMID:19159436 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ifng interferon gamma multiple interactions ISO Niacin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] CTD PMID:19159436 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL1B protein]; Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein] CTD PMID:17516992 PMID:19159436 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il6 interleukin 6 multiple interactions EXP
ISO
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 mRNA]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of IL6 protein]; Niacin inhibits the reaction [Rotenone results in increased expression of IL6 protein]
[Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL6 protein]
CTD PMID:17516992 PMID:20975550 PMID:31820278 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Kdr kinase insert domain receptor increases expression ISO Niacin results in increased expression of KDR mRNA CTD PMID:17557352 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
JBrowse link
G Kras KRAS proto-oncogene, GTPase affects localization ISO Niacin affects the localization of KRAS protein CTD PMID:12106604 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Lep leptin increases expression ISO Niacin results in increased expression of LEP protein
Niacin results in increased expression of LEP mRNA
CTD PMID:16887123 PMID:21236357 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lepr leptin receptor multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of BTC mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of CIDEA mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of DDHD1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of NET1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of PCK1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of TTPA mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of UCP1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ASPH mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of CASQ1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of EDNRB mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ENO3 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of GPI1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of NRAP mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of PI16 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of RALGAPA1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of SRL mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TLN1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TPM1 mRNA] CTD PMID:16940432 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
JBrowse link
G Lipe lipase E, hormone sensitive type decreases activity
decreases expression
ISO Niacin results in decreased activity of LIPE protein
Niacin results in decreased expression of LIPE mRNA
CTD PMID:14749208 PMID:19131065 NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor increases expression EXP Niacin results in increased expression of LITAF mRNA CTD PMID:20303128 NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
JBrowse link
G Map2 microtubule-associated protein 2 increases expression EXP Niacin results in increased expression of MAP2 mRNA CTD PMID:20303128 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein; [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK1 protein; Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK1 protein] CTD PMID:16389067 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein; [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK3 protein; Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK3 protein] CTD PMID:16389067 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mlxipl MLX interacting protein-like decreases expression EXP Niacin results in decreased expression of MLXIPL protein CTD PMID:19878707 NCBI chr12:21,542,964...21,577,120
Ensembl chr12:21,543,576...21,577,112
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions EXP Niacin results in decreased phosphorylation of and results in decreased activity of MTOR protein CTD PMID:12837665 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Ncf1 neutrophil cytosolic factor 1 decreases expression EXP Niacin results in decreased expression of NCF1 protein CTD PMID:19420110 NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
JBrowse link
G Net1 neuroepithelial cell transforming 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of NET1 mRNA] CTD PMID:16940432 NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases expression EXP Niacin results in decreased expression of NFKB1 protein CTD PMID:19420110 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of NFKBIA protein]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of NFKBIA protein] CTD PMID:20975550 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP Niacin inhibits the reaction [Silicon Dioxide results in increased expression of and results in increased activity of NOS2 protein] CTD PMID:15182488 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nos3 nitric oxide synthase 3 increases expression
increases phosphorylation
multiple interactions
ISO
EXP
Niacin results in increased expression of NOS3 mRNA
Niacin results in increased phosphorylation of NOS3 protein
[Niacin co-treated with Chromium] inhibits the reaction [CAV1 protein binds to NOS3 protein]; [Niacin co-treated with Chromium] results in increased phosphorylation of NOS3 protein
CTD PMID:17557352 PMID:19027847 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
JBrowse link
G Notch1 notch receptor 1 increases expression EXP Niacin results in increased expression of NOTCH1 protein CTD PMID:19223914 NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
JBrowse link
G Nox4 NADPH oxidase 4 decreases expression EXP Niacin results in decreased expression of NOX4 protein CTD PMID:19420110 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 increases expression
multiple interactions
ISO Niacin results in increased expression of NR1H3 mRNA
PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin results in increased expression of NR1H3 mRNA]; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
CTD PMID:15037193 PMID:19797938 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
JBrowse link
G Nrap nebulin-related anchoring protein multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of NRAP mRNA] CTD PMID:16940432 NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693
JBrowse link
G Ntrk2 neurotrophic receptor tyrosine kinase 2 increases expression EXP Niacin results in increased expression of NTRK2 protein CTD PMID:20671245 NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
JBrowse link
G Olr1 oxidized low density lipoprotein receptor 1 multiple interactions EXP [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of OLR1 mRNA]; [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of OLR1 protein] CTD PMID:18622720 NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO
EXP
[Niacin co-treated with Ubiquinone co-treated with Riboflavin] results in increased expression of PARP1 protein
Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein]
CTD PMID:17516866 PMID:18377693 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 decreases expression
multiple interactions
EXP
ISO
Niacin results in decreased expression of PCK1 mRNA
LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of PCK1 mRNA]
CTD PMID:16940432 PMID:20303128 NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 increases expression EXP Niacin results in increased expression of PDK4 mRNA CTD PMID:20303128 NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions
decreases expression
ISO Niacin inhibits the reaction [TNF protein results in increased expression of PECAM1 protein]
Niacin results in decreased expression of PECAM1 protein
CTD PMID:19159436 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
JBrowse link
G Pi16 peptidase inhibitor 16 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of PI16 mRNA] CTD PMID:16940432 NCBI chr20:7,376,073...7,385,386
Ensembl chr20:7,376,126...7,385,383
JBrowse link
G Pla2g7 phospholipase A2 group VII decreases expression ISO Niacin results in decreased expression of PLA2G7 protein CTD PMID:16950175 NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression EXP
ISO
Niacin results in increased expression of PPARA protein
Niacin results in increased expression of PPARA mRNA
CTD PMID:18602814 PMID:19878707 PMID:24767308 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Niacin results in increased activity of PPARG protein]; Aspirin inhibits the reaction [Niacin results in increased activity of PPARG protein]; HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein]; HCAR3 protein promotes the reaction [Niacin results in increased activity of PPARG protein]; Niacin results in increased expression of and results in increased activity of PPARG protein; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]; PTGDS protein promotes the reaction [Niacin results in increased activity of PPARG protein]; PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein]
Niacin results in increased expression of PPARG mRNA
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG protein; fluprostenol inhibits the reaction [Niacin results in increased expression of PPARG mRNA]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; PPARG protein promotes the reaction [Niacin results in increased expression of ABCA1 mRNA]; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
CTD PMID:15037193 PMID:16386710 PMID:19131065 PMID:19797938 PMID:21236357 More... NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression ISO Niacin results in increased expression of PPARGC1A mRNA CTD PMID:23056435 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 increases activity ISO Niacin results in increased activity of PRKAA2 protein CTD PMID:14749208 NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO [MK-0524 binds to and results in decreased activity of PTGDR protein] which results in decreased susceptibility to Niacin CTD PMID:17392721 NCBI chr15:17,360,304...17,367,679 JBrowse link
G Ptgds prostaglandin D2 synthase multiple interactions ISO PTGDS protein promotes the reaction [Niacin results in increased activity of PPARG protein] CTD PMID:16386710 NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions
decreases expression
increases response to substance
ISO
EXP
PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein]
Niacin results in decreased expression of PTGS1 protein
PTGS1 protein results in increased susceptibility to Niacin
CTD PMID:16322797 PMID:16386710 PMID:19420110 NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
decreases expression
ISO [Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]] which results in decreased expression of PTGS2 mRNA; [Niacin results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprost; Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]
Niacin results in decreased expression of PTGS2 mRNA; Niacin results in decreased expression of PTGS2 protein
CTD PMID:21236357 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Qprt quinolinate phosphoribosyltransferase increases abundance EXP QPRT protein results in increased abundance of Niacin CTD PMID:11758903 NCBI chr 1:181,718,189...181,733,486
Ensembl chr 1:181,718,190...181,733,486
JBrowse link
G Ralgapa1 Ral GTPase activating protein catalytic subunit alpha 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of RALGAPA1 mRNA] CTD PMID:16940432 NCBI chr 6:72,977,432...73,252,378
Ensembl chr 6:72,977,432...73,252,378
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases expression
EXP
ISO
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of and results in increased activity of RELA protein]
Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]
Niacin results in decreased expression of RELA protein
CTD PMID:18550065 PMID:19420110 PMID:20975550 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Retn resistin decreases expression ISO Niacin results in decreased expression of RETN protein CTD PMID:16979396 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions EXP Niacin results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein CTD PMID:12837665 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Rtn4r reticulon 4 receptor decreases expression EXP Niacin results in decreased expression of RTN4R protein CTD PMID:20671245 NCBI chr11:82,844,585...82,869,012
Ensembl chr11:82,844,309...82,869,466
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions
decreases expression
increases expression
ISO
EXP
Aspirin inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA]; Niacin promotes the reaction [SCARB1 protein results in increased export of Cholesterol, HDL]; Ro 31-8220 inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA]
Niacin results in decreased expression of SCARB1 protein
CTD PMID:15037193 PMID:19878707 PMID:21291703 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]
Niacin results in decreased expression of SERPINE1 protein
CTD PMID:16916501 PMID:19420110 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
JBrowse link
G Sirt2 sirtuin 2 increases expression ISO Niacin deficiency results in increased expression of SIRT2 mRNA CTD PMID:22860104 NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
JBrowse link
G Sirt4 sirtuin 4 increases expression ISO Niacin deficiency results in increased expression of SIRT4 mRNA CTD PMID:22860104 NCBI chr12:41,125,533...41,139,440
Ensembl chr12:41,131,262...41,139,439
JBrowse link
G Slc16a1 solute carrier family 16 member 1 increases import EXP SLC16A1 protein results in increased import of Niacin CTD PMID:10579682 NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
JBrowse link
G Slc22a7 solute carrier family 22 member 7 multiple interactions EXP
ISO
Niacin promotes the reaction [SLC22A7 protein results in increased export of Orotic Acid] CTD PMID:22981274 NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
JBrowse link
G Slc27a2 solute carrier family 27 member 2 increases expression ISO Niacin results in increased expression of SLC27A2 mRNA CTD PMID:24767308 NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
JBrowse link
G Slc27a4 solute carrier family 27 member 4 increases expression ISO Niacin results in increased expression of SLC27A4 mRNA CTD PMID:24767308 NCBI chr 3:13,075,022...13,087,943
Ensembl chr 3:13,075,022...13,087,943
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP [Niacin co-treated with Chromium] promotes the reaction [SLC2A4 protein binds to CAV3 protein]; [Niacin co-treated with Chromium] results in increased localization of SLC2A4 protein CTD PMID:19027847 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Slc4a2 solute carrier family 4 member 2 increases uptake ISO SLC4A2 protein results in increased uptake of Niacin CTD PMID:9563070 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
JBrowse link
G Snca synuclein alpha multiple interactions ISO [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Niacin inhibits the reaction [Rotenone results in increased expression of SNCA protein] CTD PMID:31820278 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
JBrowse link
G Spink5 serine peptidase inhibitor, Kazal type 5 increases expression EXP Niacin results in increased expression of SPINK5 mRNA CTD PMID:20303128 NCBI chr18:36,264,452...36,333,143
Ensembl chr18:36,264,452...36,332,185
JBrowse link
G Srl sarcalumenin multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of SRL mRNA] CTD PMID:16940432 NCBI chr10:11,033,976...11,078,103
Ensembl chr10:11,034,035...11,078,101
JBrowse link
G St6gal1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 increases expression EXP Niacin results in increased expression of ST6GAL1 mRNA CTD PMID:20303128 NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions EXP [[Niacin co-treated with Chromium] results in increased expression of STAR protein] which results in increased export of Cholesterol; [Niacin co-treated with Chromium] results in increased expression of STAR protein CTD PMID:17934701 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases activity EXP Niacin results in decreased activity of STAT5A protein CTD PMID:15746188 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
JBrowse link
G Syp synaptophysin increases expression EXP Niacin results in increased expression of SYP protein CTD PMID:20671245 NCBI chr  X:14,849,444...14,864,553
Ensembl chr  X:14,849,444...14,864,745
JBrowse link
G Tek TEK receptor tyrosine kinase increases expression
increases phosphorylation
EXP Niacin results in increased expression of TEK mRNA
Niacin results in increased phosphorylation of TEK protein
CTD PMID:17557352 NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
JBrowse link
G Tesc tescalcin increases expression EXP Niacin results in increased expression of TESC mRNA CTD PMID:20303128 NCBI chr12:38,521,839...38,555,665
Ensembl chr12:38,521,861...38,555,824
JBrowse link
G Tfrc transferrin receptor decreases expression EXP Niacin results in decreased expression of TFRC protein CTD PMID:18549825 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
ISO
EXP
Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 mRNA]; Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein]; Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]
Niacin results in decreased expression of TGFB1 protein
CTD PMID:16916501 PMID:19337903 PMID:19420110 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tln1 talin 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TLN1 mRNA] CTD PMID:16940432 NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
[Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of TNF protein]; Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Niacin inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Niacin inhibits the reaction [TNF protein results in increased expression of PECAM1 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
CTD PMID:16916501 PMID:17516992 PMID:18550065 PMID:19159436 PMID:20975550 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tp53 tumor protein p53 affects expression
decreases expression
multiple interactions
EXP Niacin deficiency affects the expression of TP53 protein
Niacin deficiency results in decreased expression of TP53 mRNA
Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]
CTD PMID:17516866 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tpm1 tropomyosin 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TPM1 mRNA] CTD PMID:16940432 NCBI chr 8:67,635,479...67,662,330
Ensembl chr 8:67,635,479...67,662,802
JBrowse link
G Ttpa alpha tocopherol transfer protein multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of TTPA mRNA] CTD PMID:16940432 NCBI chr 5:33,497,537...33,518,936
Ensembl chr 5:33,497,137...33,518,073
JBrowse link
G Ucp1 uncoupling protein 1 multiple interactions ISO LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of UCP1 mRNA] CTD PMID:16940432 NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO Niacin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] CTD PMID:18550065 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO
EXP
Niacin results in increased expression of VEGFA mRNA CTD PMID:17557352 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Vtn vitronectin increases expression ISO Niacin results in increased expression of VTN protein CTD PMID:20539903 NCBI chr10:63,394,732...63,397,812
Ensembl chr10:63,394,719...63,397,810
JBrowse link
picloram term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Foxo1 forkhead box O1 decreases expression
multiple interactions
ISO Picloram results in decreased expression of FOXO1 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of FOXO1 mRNA]
CTD PMID:21318024 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 decreases expression
multiple interactions
ISO Picloram results in decreased expression of GRIN1 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of GRIN1 mRNA]
CTD PMID:21318024 NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
JBrowse link
G Mt-atp6 mitochondrially encoded ATP synthase membrane subunit 6 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of ATP6 mRNA] CTD PMID:21318024 Ensembl chr MT:7,919...8,599 JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I decreases expression
multiple interactions
ISO Picloram results in decreased expression of COX1 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of COX1 mRNA]
CTD PMID:21318024 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Mt-cyb mitochondrially encoded cytochrome b multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of CYTB mRNA] CTD PMID:21318024 NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
JBrowse link
G Mt-nd1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of ND1 mRNA] CTD PMID:21318024 NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression ISO Picloram results in increased expression of PPARGC1A mRNA CTD PMID:21318024 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
JBrowse link
G Prdx1 peroxiredoxin 1 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX1 mRNA] CTD PMID:21318024 NCBI chr 5:130,147,276...130,162,850
Ensembl chr 5:130,147,204...130,162,856
JBrowse link
G Prdx2 peroxiredoxin 2 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX2 mRNA] CTD PMID:21318024 NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
JBrowse link
G Prdx3 peroxiredoxin 3 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX3 mRNA] CTD PMID:21318024 NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
JBrowse link
G Prdx4 peroxiredoxin 4 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX4 mRNA] CTD PMID:21318024 NCBI chr  X:40,026,762...40,044,066
Ensembl chr  X:40,026,651...40,044,066
JBrowse link
G Prdx5 peroxiredoxin 5 decreases expression
multiple interactions
ISO Picloram results in decreased expression of PRDX5 mRNA
arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX5 mRNA]
CTD PMID:21318024 NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
JBrowse link
G Prdx6 peroxiredoxin 6 multiple interactions
decreases expression
ISO arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX6 mRNA] CTD PMID:21318024 NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355
JBrowse link
picolinic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 decreases expression ISO picolinic acid results in decreased expression of ABCA1 protein CTD PMID:16870493 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP [picolinic acid co-treated with Linoleic Acids, Conjugated] results in increased expression of ADIPOQ protein CTD PMID:17199723 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP picolinic acid inhibits the reaction [Cisplatin results in increased expression of BAX protein] CTD PMID:20817559 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Casp3 caspase 3 decreases activity
increases activity
ISO picolinic acid results in decreased activity of CASP3 protein
picolinic acid results in increased activity of CASP3 protein
CTD PMID:19853652 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO picolinic acid inhibits the reaction [Glucose results in increased secretion of CCL2 protein] CTD PMID:17665966 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Cd36 CD36 molecule affects localization ISO picolinic acid affects the localization of CD36 protein CTD PMID:20721637 NCBI chr 4:17,317,343...17,410,084 JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO ferrous sulfate inhibits the reaction [picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:10799651 PMID:10823667 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 decreases glycation ISO picolinic acid results in decreased glycation of HBA1 protein CTD PMID:22944053 NCBI chr10:15,323,830...15,324,677 JBrowse link
G Hspd1 heat shock protein family D (Hsp60) member 1 multiple interactions EXP picolinic acid inhibits the reaction [Cisplatin results in increased expression of HSPD1 protein] CTD PMID:20817559 NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions EXP picolinic acid promotes the reaction [INS1 protein results in increased expression of IGF1 mRNA] CTD PMID:20013160 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions EXP picolinic acid promotes the reaction [INS1 protein results in increased expression of IGF1R mRNA] CTD PMID:20013160 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
JBrowse link
G Il6 interleukin 6 multiple interactions ISO picolinic acid inhibits the reaction [Glucose results in increased secretion of IL6 protein] CTD PMID:17665966 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Insr insulin receptor increases expression EXP picolinic acid results in increased expression of INSR mRNA CTD PMID:19283340 NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP picolinic acid inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 protein] CTD PMID:22790776 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions EXP picolinic acid inhibits the reaction [Streptozocin results in decreased expression of NFKBIA protein] CTD PMID:22790776 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Retn resistin decreases secretion ISO picolinic acid results in decreased secretion of RETN protein CTD PMID:19298540 NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions
affects localization
ISO [Glucose co-treated with picolinic acid] affects the localization of SLC2A4 protein
picolinic acid affects the localization of SLC2A4 protein
CTD PMID:16339278 PMID:16870493 PMID:19195868 PMID:20721637 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 affects localization ISO picolinic acid affects the localization of SREBF1 protein CTD PMID:16870493 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP picolinic acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; picolinic acid inhibits the reaction [Streptozocin results in increased secretion of TNF protein] CTD PMID:17854708 PMID:20817559 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Ubc ubiquitin C multiple interactions
decreases expression
EXP picolinic acid promotes the reaction [INS1 protein results in decreased expression of UBC mRNA]
picolinic acid results in decreased expression of UBC mRNA
CTD PMID:20013160 NCBI chr12:31,238,889...31,243,924
Ensembl chr12:31,239,152...31,243,925
JBrowse link
G Ucp3 uncoupling protein 3 increases expression EXP picolinic acid results in increased expression of UCP3 mRNA CTD PMID:19283340 NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19812
    role 19761
      chemical role 19336
        donor 18644
          Bronsted acid 18526
            oxoacid 18488
              carbon oxoacid 18369
                carboxylic acid 18364
                  monocarboxylic acid 17632
                    pyridinemonocarboxylic acid 403
                      (5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone 0
                      2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-(methoxymethyl)nicotinic acid + 2
                      2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)nicotinic acid + 1
                      2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                      2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                      2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                      2-ethylisonicotinic acid 0
                      5-(2'-formylethyl)-4,6-dihydroxypicolinic acid 0
                      5-formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid 0
                      5-methyl-2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]pyridine-3-carboxylic acid + 0
                      5-pyridoxic acid + 0
                      Ancriviroc 4
                      Isoniazid calcium pyruvate 0
                      LSM-11632 0
                      LSM-12915 0
                      LSM-14259 0
                      LSM-14448 0
                      LSM-14622 0
                      LSM-14627 0
                      LSM-8759 0
                      LSM-9231 0
                      LSM-9415 0
                      LSM-9543 0
                      N'-[(2-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                      N'-[(3-nitro-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]-4-pyridinecarbohydrazide 0
                      N'-[(3-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                      N'-[(4-methoxy-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-pyridinecarbohydrazide 0
                      N-(1-thiophen-2-ylethylideneamino)-4-pyridinecarboxamide 0
                      N-[(4-phenylmethoxyphenyl)methylideneamino]-1-(phenylmethyl)-4-pyridin-1-iumcarboxamide 0
                      N-[(4-tert-butylphenyl)methylideneamino]-2-pyridinecarboxamide 0
                      N-[(5-bromo-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                      N-[(5-nitro-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                      N-[1-(5-nitro-2-tetrazolyl)propan-2-ylideneamino]-4-pyridinecarboxamide 0
                      N-[[2-(1H-imidazol-2-yl)-1-phenylethylidene]amino]-4-pyridinecarboxamide 0
                      N-[[4-(4-fluoroanilino)-4-oxobutan-2-ylidene]amino]-2-pyridinecarboxamide 0
                      N-[[4-[(2-chloro-5-thiazolyl)methoxy]-3-methoxyphenyl]methylideneamino]-4-pyridinecarboxamide 0
                      [3-(2-furanyl)-5-(thiophen-2-ylmethylamino)-1,2,4-triazol-1-yl]-(3-pyridinyl)methanone 0
                      [4-[(3-bromophenyl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                      [4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                      [5-(4-bromophenyl)-3-(2-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone 0
                      clitidine 0
                      clonixin 0
                      florpyrauxifen + 0
                      flunixin 1
                      furonazide 0
                      glyconiazide 0
                      halauxifen + 0
                      isonicotinic acid + 168
                      methaniazide 0
                      monoethyl malonate 0
                      nicotinic acid + 255
                      piberaline 0
                      picloram + 13
                      picolinic acid + 34
                      salinazid 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19812
    subatomic particle 19811
      composite particle 19811
        hadron 19811
          baryon 19811
            nucleon 19811
              atomic nucleus 19811
                atom 19811
                  main group element atom 19708
                    p-block element atom 19708
                      carbon group element atom 19630
                        carbon atom 19620
                          organic molecular entity 19620
                            organic group 18728
                              organic divalent group 18719
                                organodiyl group 18719
                                  carbonyl group 18667
                                    carbonyl compound 18667
                                      carboxylic acid 18364
                                        monocarboxylic acid 17632
                                          pyridinemonocarboxylic acid 403
                                            (5-bromo-3-pyridinyl)-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone 0
                                            2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-(methoxymethyl)nicotinic acid + 2
                                            2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)nicotinic acid + 1
                                            2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                                            2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                                            2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[oxo(pyridin-4-yl)methyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetic acid 0
                                            2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-propylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3,5-difluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                            2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(pyridine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(pyridine-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                            2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                            2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                            2-ethylisonicotinic acid 0
                                            5-(2'-formylethyl)-4,6-dihydroxypicolinic acid 0
                                            5-formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid 0
                                            5-methyl-2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]pyridine-3-carboxylic acid + 0
                                            5-pyridoxic acid + 0
                                            Ancriviroc 4
                                            Isoniazid calcium pyruvate 0
                                            LSM-11632 0
                                            LSM-12915 0
                                            LSM-14259 0
                                            LSM-14448 0
                                            LSM-14622 0
                                            LSM-14627 0
                                            LSM-8759 0
                                            LSM-9231 0
                                            LSM-9415 0
                                            LSM-9543 0
                                            N'-[(2-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                                            N'-[(3-nitro-4-oxo-1-cyclohexa-2,5-dienylidene)methyl]-4-pyridinecarbohydrazide 0
                                            N'-[(3-nitrophenyl)-oxomethyl]-2-pyridinecarbohydrazide 0
                                            N'-[(4-methoxy-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2-pyridinecarbohydrazide 0
                                            N-(1-thiophen-2-ylethylideneamino)-4-pyridinecarboxamide 0
                                            N-[(4-phenylmethoxyphenyl)methylideneamino]-1-(phenylmethyl)-4-pyridin-1-iumcarboxamide 0
                                            N-[(4-tert-butylphenyl)methylideneamino]-2-pyridinecarboxamide 0
                                            N-[(5-bromo-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                                            N-[(5-nitro-2-thiophenyl)methylideneamino]-2-pyridinecarboxamide 0
                                            N-[1-(5-nitro-2-tetrazolyl)propan-2-ylideneamino]-4-pyridinecarboxamide 0
                                            N-[[2-(1H-imidazol-2-yl)-1-phenylethylidene]amino]-4-pyridinecarboxamide 0
                                            N-[[4-(4-fluoroanilino)-4-oxobutan-2-ylidene]amino]-2-pyridinecarboxamide 0
                                            N-[[4-[(2-chloro-5-thiazolyl)methoxy]-3-methoxyphenyl]methylideneamino]-4-pyridinecarboxamide 0
                                            [3-(2-furanyl)-5-(thiophen-2-ylmethylamino)-1,2,4-triazol-1-yl]-(3-pyridinyl)methanone 0
                                            [4-[(3-bromophenyl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                                            [4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-(3-pyridinyl)methanone 0
                                            [5-(4-bromophenyl)-3-(2-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone 0
                                            clitidine 0
                                            clonixin 0
                                            florpyrauxifen + 0
                                            flunixin 1
                                            furonazide 0
                                            glyconiazide 0
                                            halauxifen + 0
                                            isonicotinic acid + 168
                                            methaniazide 0
                                            monoethyl malonate 0
                                            nicotinic acid + 255
                                            piberaline 0
                                            picloram + 13
                                            picolinic acid + 34
                                            salinazid 0
paths to the root